Centergate Subsidiary Gains Clinical Trial Clearance for Methylphenidate Prolonged-Release Chewable Tablet

Stock News

昨天

Beijing Centergate Technologies (Holding) Co., Ltd. has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a "Drug Clinical Trial Approval Notice" from China's National Medical Products Administration for methylphenidate hydrochloride prolonged-release chewable tablets (40mg dosage).

The medication has been cleared for clinical trials targeting attention deficit hyperactivity disorder (ADHD).

According to current statistics, only one original imported drug has received market approval in China for this indication. This approval positions Beijing Huasu as the first domestic pharmaceutical company to obtain clinical trial permission for a generic version of this treatment.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1147997181"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147997181\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147997181?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147997181","market":"us","top_or_hot":-1,"title":"Centergate Subsidiary Gains Clinical Trial Clearance for Methylphenidate Prolonged-Release Chewable Tablet","media":"Stock News","content":"<p><b>Beijing Centergate Technologies (Holding) Co., Ltd.</b> has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a \"Drug Clinical Trial Approval Notice\" from China's National Medical Products Administration for methylphenidate hydrochloride prolonged-release chewable tablets (40mg dosage).<br><br>The medication has been cleared for clinical trials targeting attention deficit hyperactivity disorder (ADHD).<br><br>According to current statistics, only one original imported drug has received market approval in China for this indication. This approval positions Beijing Huasu as the first domestic pharmaceutical company to obtain clinical trial permission for a generic version of this treatment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Centergate Subsidiary Gains Clinical Trial Clearance for Methylphenidate Prolonged-Release Chewable Tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentergate Subsidiary Gains Clinical Trial Clearance for Methylphenidate Prolonged-Release Chewable Tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-01 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Beijing Centergate Technologies (Holding) Co., Ltd.</b> has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a \"Drug Clinical Trial Approval Notice\" from China's National Medical Products Administration for methylphenidate hydrochloride prolonged-release chewable tablets (40mg dosage).<br><br>The medication has been cleared for clinical trials targeting attention deficit hyperactivity disorder (ADHD).<br><br>According to current statistics, only one original imported drug has received market approval in China for this indication. This approval positions Beijing Huasu as the first domestic pharmaceutical company to obtain clinical trial permission for a generic version of this treatment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000931","symbol_name":"中关村","start_time":0,"source_url":"","article_id":"1147997181","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147997181","pubTimestamp":1788253380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Centergate Technologies (Holding) Co., Ltd. has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a \"Drug Clinical Trial Approval Notice\" from China's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"000931":"中关村","BK0239":"医药制造","BK0028":"国家队","BK0075":"新三板","BK0178":"特色小镇","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","PSYK":"PSYK ETF","MDTX":"Corgi MediaTek 2x Daily ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF"},"translate_title":"Centergate子公司获得哌醋甲酯缓释咀嚼片临床试验许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000931":1,"BMED":1,"IBBQ":1,"IBBJ":1,"MDTX":1,"PSYK":1},"content_text":"Beijing Centergate Technologies (Holding) Co., Ltd. has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a \"Drug Clinical Trial Approval Notice\" from China's National Medical Products Administration for methylphenidate hydrochloride prolonged-release chewable tablets (40mg dosage).The medication has been cleared for clinical trials targeting attention deficit hyperactivity disorder (ADHD).According to current statistics, only one original imported drug has received market approval in China for this indication. This approval positions Beijing Huasu as the first domestic pharmaceutical company to obtain clinical trial permission for a generic version of this treatment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}